翻訳と辞書 |
ABT-510 ABT-510 is a molecular therapeutic drug that was the subject of research as a potential treatment for cancer. According to the ''Journal of Clinical Oncology'', ABT-510 is a "subcutaneously (SC) administered nonapeptide thrombospondin analogue."〔(NCI: ABT-510 )〕 Following inconclusive phase I clinical trials, a 2007 phase II study of ABT-510 for treatment of metastatic melanoma failed to reach its primary endpoint resulting in termination of the study. Only three out of twenty-one patients reached the primary endpoint of progression-free survival at 18 weeks, but these three patients remained progression-free for 21, 34, and 42 weeks. However, biomarker data collected during this study showed a decrease in VEGF-C, circulating endothelial cells, and CD146 and CD34/133 counts, and a maximum tolerated dose has still not been established. Further study could consider a higher dose and/or combination treatment. ==References==
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「ABT-510」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|